13 December 2018 1 Min Read
Aspen could sell portfolio for R1.9bn
US-headquartered pharmaceutical group Mylan will have option to buy portfolio
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In